- Home
- SLNO vs CGON Comparison
SLNO vs CGON Comparison
Compare SLNO & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- CGON
- Stock Information
- Founded
- SLNO 1999
- CGON 2010
- Country
- SLNO United States
- CGON United States
- Employees
- SLNO N/A
- CGON N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CGON
- Sector
- SLNO Health Care
- CGON
- Exchange
- SLNO Nasdaq
- CGON NYSE
- Market Cap
- SLNO 2.2B
- CGON 2.3B
- IPO Year
- SLNO 2014
- CGON 2024
- Fundamental
- Price
- SLNO $46.13
- CGON $27.85
- Analyst Decision
- SLNO Strong Buy
- CGON Strong Buy
- Analyst Count
- SLNO 5
- CGON 10
- Target Price
- SLNO $71.20
- CGON $65.11
- AVG Volume (30 Days)
- SLNO 390.6K
- CGON 421.1K
- Earning Date
- SLNO 03-05-2025
- CGON 03-04-2025
- Dividend Yield
- SLNO N/A
- CGON N/A
- EPS Growth
- SLNO N/A
- CGON N/A
- EPS
- SLNO N/A
- CGON N/A
- Revenue
- SLNO N/A
- CGON $684,000.00
- Revenue This Year
- SLNO N/A
- CGON $210.00
- Revenue Next Year
- SLNO N/A
- CGON N/A
- P/E Ratio
- SLNO N/A
- CGON N/A
- Revenue Growth
- SLNO N/A
- CGON 258.12
- 52 Week Low
- SLNO $36.61
- CGON $25.77
- 52 Week High
- SLNO $60.92
- CGON $48.05
- Technical
- Relative Strength Index (RSI)
- SLNO 40.51
- CGON 41.49
- Support Level
- SLNO $48.48
- CGON $27.10
- Resistance Level
- SLNO $52.46
- CGON $29.42
- Average True Range (ATR)
- SLNO 2.07
- CGON 1.15
- MACD
- SLNO -0.47
- CGON -0.10
- Stochastic Oscillator
- SLNO 0.94
- CGON 29.02
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.